Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism

OHTS 中青光眼的遗传因素;

基本信息

  • 批准号:
    10716352
  • 负责人:
  • 金额:
    $ 41.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-30 至 2028-01-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Glaucoma is a common cause of severe vision loss, characterized by the progressive loss of retinal ganglion cells. Several large genome-wide association studies (GWAS) for primary open angle glaucoma (POAG) have been performed to date and have discovered over 127 risk factor genes. The mechanism by which these genes lead to POAG is almost completely unknown. Our proposal seeks to 1) translate these risk factor gene discoveries into useful data for patients and their doctors and 2) determine the mechanisms by which risk factor genes confer risk. This proposal will leverage the results of prior GWAS studies along with the unmatched, 20-years of prospective clinical data from the Ocular Hypertension Treatment Study (OHTS) to develop a POAG risk calculator that includes both clinical and genetic risk factors that will be useful to patients and doctors (AIM1A). We will also conduct association studies of the OHTS cohort to identify genetic risk factors for rapid progression of POAG as measured by visual field parameters, with validation in a local Iowa cohort (AIM1B). Identifying genes associated with progression of glaucoma has great potential to personalize and guide glaucoma management. We will also investigate the functional consequences of specific glaucoma risk alleles with a range of complementary technologies. AIM2A will test the effects of risk alleles on gene expression and pathways with studies of genotyped human donor eyes using single-cell RNA sequencing (scRNAseq). Immunohistochemistry and ELISA of genotyped human donor eyes will also be used to determine the effects of risk alleles on the abundance and localization of the proteins they encode. Finally, in AIM2B will use BiT- STARR-seq to locate the specific variants (SNPs) in glaucoma loci that confer risk for glaucoma. These studies will begin to define the precise molecular steps that connect the presence of specific genetic risk factors in one’s genome to the development of glaucoma. Our proposal will lead to improved tools for ascertainment of a patient’s risk for POAG or risk for rapid worsening of POAG that can be readily transferred to clinicians in the form of better diagnostic and prognostic tools. Our proposal will also define the specific mechanisms by which risk factor alleles alter gene expression in key tissues (retinal ganglion cells), which will identify disease mechanisms and new therapeutic targets to facilitate development of targeted treatments. Our proposal has great potential to improve glaucoma care and reduce vision loss.
摘要 青光眼是一种常见的严重视力丧失的原因,其特征是视网膜神经节的进行性丧失 细胞几项针对原发性开角型青光眼(POAG)的大型全基因组关联研究(GWAS) 到目前为止,已经发现了超过127个风险因素基因。这些机制 导致原发性开角型青光眼的基因几乎完全未知。我们的建议旨在1)翻译这些风险因素基因 这些发现转化为对患者及其医生有用的数据,2)确定风险 因子基因带来风险。 该提案将利用先前GWAS研究的结果沿着20年来无与伦比的 来自高眼压治疗研究(OHTS)的前瞻性临床数据,以产生POAG风险 计算器,包括临床和遗传风险因素,这将是有用的病人和医生(AIM 1A)。 我们还将对OHTS队列进行关联研究,以确定快速发生OHTS的遗传风险因素。 通过视野参数测量POAG的进展,并在当地爱荷华州队列(AIM 1B)中进行验证。 识别与青光眼进展相关的基因具有很大的潜力, 青光眼治疗 我们还将研究特定青光眼风险等位基因的功能后果, 互补技术。AIM 2A将测试风险等位基因对基因表达和途径的影响, 使用单细胞RNA测序(scRNAseq)对人类供体眼睛进行基因分型的研究。 免疫组织化学和ELISA的基因型人类供体的眼睛也将被用来确定的影响 风险等位基因对它们编码的蛋白质的丰度和定位的影响。最后,在AIM 2B中将使用BiT- STARR-seq定位青光眼基因座中赋予青光眼风险的特定变体(SNP)。这些研究 将开始定义精确的分子步骤,这些步骤将特定的遗传风险因素的存在联系起来, 基因组与青光眼的发展有关。 我们的建议将导致改进的工具,以确定患者的风险POAG或风险的快速 POAG恶化,可以很容易地以更好的诊断和预后的形式转移给临床医生 工具.我们的建议也将定义危险因子等位基因改变基因表达的具体机制 在关键组织(视网膜神经节细胞)中,这将确定疾病机制和新的治疗靶点, 促进靶向治疗的发展。我们的建议有很大的潜力,以改善青光眼护理, 减少视力丧失。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN H FINGERT其他文献

JOHN H FINGERT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN H FINGERT', 18)}}的其他基金

TBK1-Related Glaucoma
TBK1相关青光眼
  • 批准号:
    9013186
  • 财政年份:
    2015
  • 资助金额:
    $ 41.44万
  • 项目类别:
TBK1-Related Glaucoma
TBK1相关青光眼
  • 批准号:
    9187020
  • 财政年份:
    2015
  • 资助金额:
    $ 41.44万
  • 项目类别:
Matrix Metallopeptidase 19 (MMP19) and Optic Nerve Disease
基质金属肽酶 19 (MMP19) 和视神经疾病
  • 批准号:
    8919368
  • 财政年份:
    2014
  • 资助金额:
    $ 41.44万
  • 项目类别:
Molecular Genetics of Norma Tension Glaucoma
正常眼压性青光眼的分子遗传学
  • 批准号:
    9242640
  • 财政年份:
    2014
  • 资助金额:
    $ 41.44万
  • 项目类别:
Matrix Metallopeptidase 19 (MMP19) and Optic Nerve Disease
基质金属肽酶 19 (MMP19) 和视神经疾病
  • 批准号:
    8753686
  • 财政年份:
    2014
  • 资助金额:
    $ 41.44万
  • 项目类别:
Molecular Genetics of Norma Tension Glaucoma
正常眼压性青光眼的分子遗传学
  • 批准号:
    8652634
  • 财政年份:
    2014
  • 资助金额:
    $ 41.44万
  • 项目类别:
Genetics of Quantitative Traits Associated with Glaucoma
与青光眼相关的数量性状的遗传学
  • 批准号:
    8500293
  • 财政年份:
    2009
  • 资助金额:
    $ 41.44万
  • 项目类别:
Genetics of Quantitative Traits Associated with Glaucoma
与青光眼相关的数量性状的遗传学
  • 批准号:
    7881518
  • 财政年份:
    2009
  • 资助金额:
    $ 41.44万
  • 项目类别:
Genetics of Quantitative Traits Associated with Glaucoma
与青光眼相关的数量性状的遗传学
  • 批准号:
    8288845
  • 财政年份:
    2009
  • 资助金额:
    $ 41.44万
  • 项目类别:
Genetics of Quantitative Traits Associated with Glaucoma
与青光眼相关的数量性状的遗传学
  • 批准号:
    7659174
  • 财政年份:
    2009
  • 资助金额:
    $ 41.44万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 41.44万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 41.44万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 41.44万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 41.44万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 41.44万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 41.44万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 41.44万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 41.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 41.44万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 41.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了